Diversion-p64 Post Market Clinical Follow-Up Study to Assess Safety and Effectiveness of the p64 Flow Modulation Device
Prospective, Multicenter, Single Arm Post Market Clinical Follow-Up Study to Assess Safety and Effectiveness of the p64 Flow Modulation Device
Sponsor: Phenox GmbH
This observational or N/A phase trial investigates Intracranial Aneurysm and is currently completed. Phenox GmbH leads this study, which shows 12 recorded versions since 2015 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
12 versions recorded-
Sep 2025 — Present [monthly]
Completed
-
Sep 2024 — Sep 2025 [monthly]
Completed
-
Jul 2024 — Sep 2024 [monthly]
Completed
-
Jan 2021 — Jul 2024 [monthly]
Completed
-
Dec 2020 — Jan 2021 [monthly]
Completed
Status: Active Not Recruiting → Completed
▶ Show 7 earlier versions
-
Apr 2020 — Dec 2020 [monthly]
Active Not Recruiting
-
Dec 2019 — Apr 2020 [monthly]
Active Not Recruiting
Status: Recruiting → Active Not Recruiting
-
Oct 2018 — Dec 2019 [monthly]
Recruiting
-
Jun 2018 — Oct 2018 [monthly]
Recruiting
-
Apr 2018 — Jun 2018 [monthly]
Recruiting
Phase: NA → None
-
Aug 2017 — Apr 2018 [monthly]
Recruiting NA
-
Jan 2017 — Aug 2017 [monthly]
Recruiting NA
First recorded
Dec 2015
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Phenox GmbH
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Augsburg, Germany , Bologna, Italy , Bordeaux, France , Bremen, Germany , Bron, France , Bucharest, Romania , Buenos Aires, Argentina , Edinburgh, United Kingdom , Erfurt, Germany , Genk, Belgium and 16 more locations